Jens Eilbracht

Empagliflozin in Patients with Chronic Kidney Disease

M. Landray, A. Levin, C. Wanner, 2022, The New England journal of medicine.

Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial.

M. Roden, U. Broedl, H. Woerle, 2013, The lancet. Diabetes & endocrinology.

Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4‐week, randomized, placebo‐controlled trial (EASE‐1)

T. Pieber, S. Famulla, U. Broedl, 2015, Diabetes, obesity & metabolism.

Glucose Exposure and Variability with Empagliflozin as Adjunct to Insulin in Patients with Type 1 Diabetes: Continuous Glucose Monitoring Data from a 4-Week, Randomized, Placebo-Controlled Trial (EASE-1).

T. Pieber, S. Famulla, U. Broedl, 2017, Diabetes technology & therapeutics.